AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03471091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV with the integrated tele-monitoring management program
Description: Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
Study NCT01000064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vyvanse
Description: 30 mg - 70 mg capsules taken every morning for 6 weeks.
Study NCT04264845 — intervention group
Intervention type: OTHER
Intervention: PROs/Clinical Data Integration
Description: A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
Study NCT04164160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated-care-model benefiting group
Description: Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
Study NCT02121717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chiglitazar
Description: Take orally
Study NCT01000064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: 30 mg - 70 mg capsules taken every morning for 6 weeks.
Study NCT01000064 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
Study NCT01000064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
Study NCT01000064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken every morning for 6 weeks.
Study NCT04038099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water-Based Vaginal Lubricant
Description: 5cc water based jelly applied intraurethral
Study NCT01000064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken every morning for 6 weeks.
Study NCT04844047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: refer to arm descriptors
Study NCT04844047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: refer to arm descriptors
Study NCT02268565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg aspirin daily at bedtime over a 2 week period
Study NCT02268565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill that looks like aspirin without the effects of aspirin
Study NCT01145027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast tray
Description: The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
Study NCT03716063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, every month for a course of treatment, a total of three courses
Study NCT03716063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, every month for a course of treatment, a total of three courses
Study NCT00832754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RDT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
Study NCT00832754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RDT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
Study NCT00832754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Judgement as basis for treatment of malaria with ACT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
Study NCT00832754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Judgement as basis for treatment of malaria with ACT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
Study NCT04038099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine topical
Description: 5cc 2% lidocaine jelly applied intraurethral
Study NCT01728389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone transplantation
Description: Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
Study NCT02121717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally
Study NCT02319850 — intervention group
Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Study NCT00843089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
Study NCT01148069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery combined with IMRT-IGRT
Description: Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
Study NCT02510872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET combined with CT with iodinated contrast injection
Study NCT03920618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Study NCT03920618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Study NCT03920618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study NCT02510872 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 18F-FDG PET combined with CT without injection
Study NCT03142620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg twice daily
Study NCT03142620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 1000mg twice daily
Study NCT03142620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500mg twice daily
Study NCT03142620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000IU
Study NCT00770952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Glimepiride
Description: Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks.
Study NCT00770952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks.
Study NCT02248714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna SR
Description: Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
Study NCT01008709 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Teleflex HemoLock clip
Description: Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
Study NCT01008709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aesculap U-clip
Description: Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
Study NCT02233374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early MRI and PET/CT - 2 weeks after commencing chemo/RT
Description: Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
Study NCT02233374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late MRI and PET/CT 6 weeks post chemo/RT
Description: Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
Study NCT04581122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
Study NCT01977456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
Study NCT01349751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric levobupivacaine
Description: 0.42% either isobaric levobupivacaine 3 ml spinal injection once
Study NCT01922895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus GG
Description: Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
Study NCT01922895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Probiotic
Description: Capsule manufactured without active ingredients.
Study NCT01349751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric levobupivacaine
Description: 0.42% hyperbaric levobupivacaine 3 ml spinal injection once
Study NCT00996086 — intervention group
Intervention type: DEVICE
Intervention: CRT device implant
Description: CRT device-recipients
Study NCT01770860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6660
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
Study NCT01259492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo
Study NCT01770860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4314
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
Study NCT01770860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8336
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
Study NCT01770860 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 4840
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
Study NCT02100722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Study NCT01916226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPNS
Description: Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
Study NCT01916226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FPNS Placebo
Description: Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
Study NCT01916226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
Study NCT01916226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine Placebo
Description: Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Study NCT03295786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions
Study NCT02100722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Coronary Artery Bypass Graft Surgery (CABG)
Study NCT03295786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions
Study NCT03295786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device
Study NCT03295786 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device
Study NCT04007549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief motivational interview on tobacco/alcohol risk reduction
Description: The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention.
Study NCT04007549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview on tobacco/alcohol risk reduction
Description: The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention.
Study NCT01259492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 20 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
Study NCT01259492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 30 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
Study NCT03640091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-extractive inter-radicular implant bed preparation
Description: Implant placement in mandibular molars
Study NCT02270398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training group
Description: Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
Study NCT02270398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training group
Description: Balance/gait exercises and cognitive exercises done separately.
Study NCT03564730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Knee Arthroplasty (UKA)
Description: Patient will have both knees completed under one anesthetic.
Study NCT03564730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged Knee Arthroplasty (UKA)
Description: Patient will have knees completed under 2 anesthetics.
Study NCT02100722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Stent
Description: Durable polymer zotarolimus-eluting stent
Study NCT02100722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx Stent
Description: Durable polymer zotarolimus-eluting stent
Study NCT03054974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern rehabilitation treatment
Description: PT 1 hour per day and OT 30min per day
Study NCT03054974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern rehabilitation &TCM
Description: Traditional Chinese Medicine, including massage and medicated bath
Study NCT03054974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern rehabilitation &Baimai Ruangao
Description: modern rehabilitation treatment with Baimai Ruangao and massage
Study NCT02270398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and strength training group
Description: Whole-body flexibility exercises, upper limb strengthening exercises.